220 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28686445	39	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.	Sun Yat-Sen University
28406621	65	Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.	Dart Neuroscience
28165743	37	Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.	Dart Neuroscience
27597413	58	Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.	Southern Medical University
27606546	218	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.	University of Navarra
27301679	21	Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.	Takeda Pharmaceutical
26978121	20	Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.	Sun Yat-Sen University
26789933	100	Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.	Intra-Cellular Therapies
26935942	41	Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.	Mercachem
26526739	35	Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.	Southern Medical University
25866242	55	2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.	Kaken Pharmaceutical
25801159	36	Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.	Csir-Indian Institute of Integrative Medicine
25754491	11	8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.	Mitsubishi Tanabe Pharma
25529739	43	Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.	Kyoto 607-8042
25456383	113	Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.	TBA
25455484	26	The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.	Mitsubishi Tanabe Pharma
25442307	17	Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.	Mitsubishi Tanabe Pharma
25432025	34	Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.	Sun Yat-Sen University
24856068	48	Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.	Banasthali University
24758746	36	Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.	Janssen Pharmaceutica
24702184	5	Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: a case study of PDE5 and its inhibitors.	Chinese Academy of Sciences (Cas)
23313637	14	Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.	Columbia University
23260348	91	Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.	Janssen-Cilag
18045743	49	Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR.	Universidade Federal De Lavras-Ufla
18656371	47	In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.	Universidade Federal De Lavras-Ufla
17553682	33	3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.	Sungkyunkwan University
23137303	38	Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.	Chinese Academy of Sciences
22985069	18	Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.	Sun Yat-Sen University
22780914	35	Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.	Pfizer
22607677	8	Identification of chalcones as potent and selective PDE5A1 inhibitors.	Youai
22204607	15	Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds.	University of Lille
22483586	10	Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.	Sun Yat-Sen University
22377514	75	The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.	Merck Research Laboratories
20400309	26	1-(2-(2,2,2-trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.	Pfizer
20443228	35	1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors.	Pfizer
18778098	12	Potent inhibition of human phosphodiesterase-5 by icariin derivatives.	University of Milan
17337182	23	Potent and selective xanthine-based inhibitors of phosphodiesterase 5.	Novartis Institutes of Biomedical Research
15771456	21	Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.	Johnson & Johnson Pharmaceutical Research and Development
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
15878277	42	Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.	Chinese Academy of Sciences
14521414	44	The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.	Glaxosmithkline
12213052	15	Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.	Johnson & Johnson Pharmaceutical Research & Development
11405657	123	Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.	Tanabe Seiyaku
10891111	56	4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.	Eisai
10090791	77	Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.	Tanabe Seiyaku
9191951	8	9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.	Upr 421 Du Cnrs
8709099	20	Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.	Tan£Be Seiyaku
8568820	10	Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).	Kyowa Hakka
7658441	89	Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.	Biofor
8254606	55	Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.	Eisai
8388468	37	Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.	Smithkline Beecham Pharmaceuticals
12824030	67	1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.	Tanabe Seiyaku
11755362	24	Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.	Novartis Pharma
12161123	13	A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.	Korea Institute of Science & Technology
22222034	35	The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.	Merck Research Laboratories
22142545	96	Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.	Merck Research Laboratories
22100260	30	The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.	Pfizer
21988093	316	Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.	Pfizer
21955943	47	Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.	Pfizer
21920746	1	New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam.	University of Strasburg
21983442	142	Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.	Biocrea
19447034	76	Discovery of selective PDE4B inhibitors.	Asahi Kasei Pharma
21602043	50	Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.	H. Lundbeck
21570840	44	Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1.	Merck Research Laboratories
21530250	73	Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.	Heriot-Watt University
21189023	66	Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.	German University In Cairo
21087867	30	Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.	Universit£
20937560	54	Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.	Dipartimento Di Scienze Farmaceutiche
20709547	69	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.	Merck Frosst Centre For Therapeutic Research
20450197	80	Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.	Biotie Therapies
20206015	22	Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.	German University In Cairo
19856955	2	Lorneic acids, trialkyl-substituted aromatic acids from a marine-derived actinomycete.	Nippon Suisan Kaisha
20053559	55	Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.	Korea Research Institute of Chemical Technology
20196613	32	Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).	Pfizer
19906530	22	Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).	Chong Kun Dang Research Institute
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
19919087	55	Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.	Pfizer
19540112	33	Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.	Pfizer
19539468	6	Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.	Pfizer
	5	The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditions	TBA
	71	Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I)	TBA
	36	Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction	TBA
19339180	69	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.	Pfizer
19272774	12	Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.	Bristol-Myers Squibb Pharmaceutical Research Institute
19049349	107	Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.	Georgia State University
18976905	35	Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.	Chong Kun Dang Research Institute
18951784	19	Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.	Pfizer
18393409	16	Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.	State University of Campinas
17107795	13	PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.	Inserm U761 Biostructures and Drug Discovery Lille
16913726	33	Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.	Università
16337379	14	Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.	Sumitomo Pharmaceuticals
16275071	26	A new chemical tool for exploring the physiological function of the PDE2 isozyme.	Pfizer
16263279	37	A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.	Pfizer
16005625	162	Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.	Sumitomo Pharmaceuticals
15993055	61	Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.	Bayer Healthcare
15837329	37	New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.	RhôNe-Poulenc Rorer
15837326	51	Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.	Schering-Plough Research Institute
15324877	90	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.	Pfizer
15324876	94	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.	Pfizer
15324874	169	Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.	Pfizer
15149695	24	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.	Pfizer
15125967	30	Identification of purine inhibitors of phosphodiesterase 7 (PDE7).	Bristol-Myers Squibb Pharmaceutical Research Institute
15080987	20	Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.	Ewha Womans University
15006407	15	Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.	Bristol-Myers Squibb Pharmaceutical Research Institute
14980684	52	SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.	Schering-Plough Research Institute
14736245	16	Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.	Johnson and Johnson Pharmaceutical Research and Development
14521415	44	The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.	Glaxosmithkline
12668004	76	Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.	Pfizer
12639576	37	Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.	Johnson & Johnson Pharmaceutical Research & Development
12570368	9	Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.	Bristol-Myers Squibb Pharmaceutical Research Institute
12540243	29	Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.	Johnson & Johnson Pharmaceutical Research & Development
12372521	21	Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.	Schering-Plough Research Institute
12182866	83	8-Aryl xanthines potent inhibitors of phosphodiesterase 5.	Novartis Horsham Research Centre
11958981	25	Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.	Bayer
11606139	11	Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents.	Institute of Pharmaceutical Chemistry
11549447	6	The discovery of novel, potent and selective PDE5 inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
32171616	32	Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.	Changzhou University
11297448	11	Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.	Bristol-Myers Squibb Pharmaceutical Research Institute
32603117	32	Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.	Sun Yat-Sen University
11150175	17	Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
27491708	31	Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.	Janssen Research & Development
26908025	164	PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.	Vrije Universiteit Amsterdam
10753463	5	N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.	Bristol-Myers Squibb Pharmaceutical Research Institute
32115956	46	Discovery and Optimization of ?-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.	Guangzhou University of Chinese Medicine
31158744	53	Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.	Universit£
31099559	36	Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.	Shanghai Institute of Materia Medica
31021628	50	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.	Chinese Academy of Sciences
30916555	43	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.	Sun Yat-Sen University
10197972	133	1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.	Tanabe Seiyaku
9990447	51	Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors.	Schering-Plough Research Institute
30554955	34	Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.	Changzhou University
30509781	22	Design, synthesis and evaluation of N	Kasetsart University
9873594	44	Aryl sulfonamides as selective PDE4 inhibitors.	Chiroscience
30888810	48	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.	Sun Yat-Sen University
31103902	41	Multi-target design strategies for the improved treatment of Alzheimer's disease.	China Pharmaceutical University
31235264	13	Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.	Mitsubishi Tanabe Pharma
30986068	112	Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.	TBA
9719589	13	4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.	Eisai
9435906	26	Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.	Schering-Plough Research Institute
9216839	113	Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.	Schering-Plough Research Institute
31610942	65	Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.	South China Agricultural University
8648603	101	Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.	Laboratories Glaxo Wellcome Centre De Recherches
8544172	3	Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase.	Glaxo Wellcome Research
25062128	16	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).	Amgen
24400806	101	Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.	Chiesi Farmaceutici
8201604	96	Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.	RhôNe-Poulenc Rorer
8120866	54	Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.	Smithkline Beecham Pharmaceuticals
8027992	49	Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity.	Eisai
23867165	21	Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.	Chinese Academy of Sciences
6620311	9	Optical resolution, absolute configuration, and activity of the enantiomers of proxyphylline.	TBA
30245400	167	Discovery of furyl/thienyl ?-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.	Shandong University
30148362	36	Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.	Sun Yat-Sen University
29549837	151	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.	University of Navarra
29505934	31	Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors.	Shandong University
29620890	25	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.	Glaxosmithkline
29363967	11	Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.	Sun Yat-Sen University
29545101	55	Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.	South China Agricultural University
2544722	94	Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.	Centre De Neurochimie Du Cnrs
29291443	30	Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.	Sun Yat-Sen University
29456790	5	Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189.	Pfizer
29718668	27	Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.	Pfizer
28751142	27	Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.	Central South University
28796496	67	Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.	Takeda Pharmaceutical
28759228	36	Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.	Takeda Pharmaceutical
29293004	12	Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.	Pfizer
29200281	20	Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.	Chiesi Farmaceutici
28985058	20	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease.	Columbia University
	8	Synthesis,MolecularModeling, and Biological Evaluation of Novel Tetrahydro-ß-Carboline Hydantoin and Tetrahydro-ß-Carboline Thiohydantoin Derivatives as Phosphodiesterase 5 Inhibitors	German University In Cairo
22356915	27	Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.	University of North Carolina
22284362	91	Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.	Boston College
16759100	33	A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.	Pfizer